NCT04762017View on ClinicalTrials.gov

OCS-05 in Patients With Optic Neuritis

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

February 10, 2021

Primary Completion Date

September 16, 2024

Study Completion Date

September 16, 2024

Conditions
Optic Neuritis
Interventions
DRUG

OCS-05 +SoC (corticosteroid) IV administration

OCS-05 + SoC (corticosteroid) IV administration for 5 consecutive days

OTHER

Placebo + SoC (corticosteroid) IV administration

Placebo + SoC (corticosteroid) IV administration for 5 consecutive days

Trial Locations (4)

69677

Hospices Civils de Lyon, Lyon

75013

CIC Neurosciences - La Pitié Salpêtrière, Paris

75019

Foundation Rothschild, Paris

06000

CHU - Nice, Nice

Sponsors

Lead Sponsor

Oculis

Collaborators (1)

Neurotrials
All Listed Sponsors
collaborator

Neurotrials

UNKNOWN

lead

Oculis

INDUSTRY